Hospital
Richland Parish Hospital Service District No 1-B
Richland Parish Hospital Service District No 1-B was paid $6.38M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoRICHLAND PARISH HOSPITAL SERVICE DISTRICT NO 1-B
RAYVILLE, LA 71269
RAYVILLE, LA 71269
33aNPI1255370144assigned 06/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.38M
24GClaims227,827
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#42 of 96
Median peer was paid$5.17M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,810 | $410K | |
| 2019 | 27,154 | $465K | |
| 2020 | 19,118 | $329K | |
| 2021 | 34,508 | $992K | |
| 2022 | 42,014 | $1.50M | |
| 2023 | 52,095 | $1.67M | |
| 2024incomplete | 30,128 | $1.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 13,287 | 11,000 | $2.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 8,748 | 7,528 | $1.05M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 1,068 | 845 | $262K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 332 | 273 | $246K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 2,782 | 2,292 | $185K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 2,464 | 1,821 | $158K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.2% | 5,562 | 3,689 | $141K |
| 80050 | General health panel | 2.2% | 3,653 | 3,131 | $139K |
| 80053 | Comprehensive metabolic panel | 2.1% | 20,951 | 14,911 | $135K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 750 | 587 | $134K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 25,980 | 19,334 | $132K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 2,964 | 2,675 | $125K |
106 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.9% | 1,297 | $122K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 1,437 | $104K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 1,804 | $102K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.2% | 2,970 | $78K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 3,412 | $76K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 2,254 | $72K |
| 76830 | Ultrasound, transvaginal | 1.0% | 662 | $67K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 32,587 | $64K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,794 | $63K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,996 | $57K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,061 | $56K |
| 80061 | Lipid panel | <1% | 4,442 | $47K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 953 | $46K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,075 | $41K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 386 | $27K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 324 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,757 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,007 | $22K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 254 | $20K |
| 82607 | <1% | 1,631 | $20K | |
| 84484 | <1% | 3,260 | $20K | |
| 80305 | <1% | 2,461 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,882 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 625 | $19K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 628 | $19K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 627 | $19K |
| 83880 | <1% | 953 | $18K | |
| G0378 | Hospital observation service, per hour | <1% | 26 | $16K |
| 99205 | Prolong outpt/office vis | <1% | 303 | $14K |
| 84481 | <1% | 1,184 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 50 | $12K |
| 81025 | <1% | 2,036 | $11K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 18,772 | $11K |
| 82553 | <1% | 2,017 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,744 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 139 | $9K |
| 82550 | <1% | 2,679 | $9K | |
| 84439 | <1% | 1,198 | $9K | |
| 81001 | <1% | 4,655 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 251 | $8K |
| 0001A | <1% | 239 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,167 | $8K |
| 0002A | <1% | 210 | $7K | |
| 93000 | <1% | 235 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 489 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 46 | $6K |
| 83690 | <1% | 1,447 | $6K | |
| 0240U | <1% | 39 | $6K | |
| 82746 | <1% | 476 | $5K | |
| 85730 | <1% | 1,703 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 39 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 580 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 27 | $4K |
| 85610 | <1% | 1,683 | $4K | |
| 81003 | <1% | 2,867 | $4K | |
| 84403 | <1% | 131 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 410 | $3K |
| 83735 | <1% | 761 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 347 | $2K |
| 83540 | <1% | 428 | $2K | |
| 74018 | <1% | 46 | $2K | |
| 84146 | <1% | 99 | $2K | |
| 83001 | <1% | 103 | $1K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 43 | $1K |
| 82670 | <1% | 59 | $1K | |
| 84100 | <1% | 416 | $964.51 | |
| 84436 | <1% | 243 | $837.28 | |
| 86780 | <1% | 76 | $797.65 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $795.92 |
| 87040 | <1% | 120 | $621.56 | |
| 86677 | <1% | 85 | $620.80 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $602.00 |
| 80150 | <1% | 52 | $545.52 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,082 | $534.28 |
| 86850 | <1% | 140 | $521.70 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 27 | $506.37 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $444.29 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 490 | $438.69 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 705 | $337.27 |
| 86901 | <1% | 141 | $312.84 | |
| 86900 | <1% | 141 | $312.84 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,416 | $261.86 |
| 82672 | <1% | 15 | $238.70 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,187 | $230.28 |
| 86803 | <1% | 20 | $228.32 | |
| 82150 | <1% | 53 | $222.84 | |
| 86140 | <1% | 66 | $218.82 | |
| 86703 | <1% | 12 | $158.07 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 570 | $141.23 |
| 86039 | <1% | 23 | $125.48 | |
| 87077 | <1% | 15 | $121.20 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,197 | $111.33 |
| J3490 | Unclassified drugs | <1% | 308 | $109.72 |
| 87070 | <1% | 12 | $103.44 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17 | $66.88 |
| 86592 | <1% | 12 | $49.58 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 80 | $26.68 |
| 82962 | <1% | 15 | $12.76 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 22 | $10.33 |
| 91300 | <1% | 666 | $5.02 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 47 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 104 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 80 | $0.00 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 281 | $0.00 |
| 81002 | 0% | 18 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPIERCE, JOANNA (DIRECTOR UTILIZATION)